Pages that link to "Q33394010"

The following pages link to Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease (Q33394010):

Displaying 50 items.

• Synanthropic rodents as possible reservoirs of shigatoxigenic Escherichia coli strains (Q21131304) ‎ (← links)
• Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection (Q27003178) ‎ (← links)
• Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence (Q30411012) ‎ (← links)
• Shiga toxin pathogenesis: kidney complications and renal failure (Q33397541) ‎ (← links)
• Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics (Q33401572) ‎ (← links)
• Renal and neurological involvement in typical Shiga toxin-associated HUS. (Q33403361) ‎ (← links)
• A novel murine infection model for Shiga toxin-producing Escherichia coli (Q33403695) ‎ (← links)
• Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals (Q33404640) ‎ (← links)
• Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells (Q33407861) ‎ (← links)
• New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome (Q33409878) ‎ (← links)
• Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure (Q33415795) ‎ (← links)
• Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease (Q33418419) ‎ (← links)
• Role of Shiga/Vero toxins in pathogenesis (Q33419440) ‎ (← links)
• Complement, thrombotic microangiopathy and disseminated intravascular coagulation (Q33420624) ‎ (← links)
• Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury (Q33433630) ‎ (← links)
• The ability of an attaching and effacing pathogen to trigger localized actin assembly contributes to virulence by promoting mucosal attachment (Q34098076) ‎ (← links)
• Renal failure in the recent 2011 Escherichia coli O104:H4 outbreak: a summary on up-to-date data (Q34129271) ‎ (← links)
• Identifying mechanisms by which Escherichia coli O157:H7 subverts interferon-γ mediated signal transducer and activator of transcription-1 activation (Q34131136) ‎ (← links)
• Recent advances in understanding enteric pathogenic Escherichia coli. (Q34375210) ‎ (← links)
• Genomic comparison of Escherichia coli O104:H4 isolates from 2009 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding phage stx2 (Q34469643) ‎ (← links)
• Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells (Q34922868) ‎ (← links)
• Commensal E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction (Q35042338) ‎ (← links)
• Glycolipid binding preferences of Shiga toxin variants (Q35199053) ‎ (← links)
• Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions (Q36060108) ‎ (← links)
• Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells (Q36744101) ‎ (← links)
• Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis (Q36837884) ‎ (← links)
• Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants. (Q37036097) ‎ (← links)
• Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL. (Q37119923) ‎ (← links)
• Retrograde trafficking of AB₅ toxins: mechanisms to therapeutics (Q37171510) ‎ (← links)
• Diminazene aceturate: an antibacterial agent for Shiga-toxin-producing Escherichia coli O157:H7. (Q37354260) ‎ (← links)
• Synchronous Disease Kinetics in a Murine Model for Enterohemorrhagic E. coli Infection Using Food-Borne Inoculation (Q37389490) ‎ (← links)
• Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy. (Q37954333) ‎ (← links)
• Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature (Q38024274) ‎ (← links)
• Ouabain Protects Human Renal Cells against the Cytotoxic Effects of Shiga Toxin Type 2 and Subtilase Cytotoxin (Q38674148) ‎ (← links)
• Genotype Cluster Analysis in Pathogenic Escherichia coli Isolates Producing Different CDT Types (Q39059706) ‎ (← links)
• Escherichia coli, cattle and the propagation of disease (Q39195548) ‎ (← links)
• Enterohemorrhagic Escherichia coli O157:H7 Shiga toxins inhibit gamma interferon-mediated cellular activation (Q39360310) ‎ (← links)
• Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea (Q42086661) ‎ (← links)
• Shiga Toxin Glycosphingolipid Receptors in Human Caco-2 and HCT-8 Colon Epithelial Cell Lines (Q47121042) ‎ (← links)
• Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). (Q49671248) ‎ (← links)
• Advances in our Understanding of the Pathogenesis of Hemolytic Uremic Syndromes. (Q49789113) ‎ (← links)
• Thrombotic Microangiopathy and the Kidney (Q50085453) ‎ (← links)
• Management of hemolytic uremic syndrome (Q57161996) ‎ (← links)
• Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects and (Q60921848) ‎ (← links)
• Prophage induction, but not production of phage particles, is required for lethal disease in a microbiome-replete murine model of enterohemorrhagic E. coli infection (Q61798627) ‎ (← links)
• Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information (Q64109746) ‎ (← links)
• The structure of the Shiga toxin 2a A-subunit dictates the interactions of the toxin with blood components (Q64237937) ‎ (← links)
• Detection of Enterohemorrhagic Escherichia Coli Colonization in Murine Host by Non-invasive In Vivo Bioluminescence System (Q88439447) ‎ (← links)
• Haemolytic uremic syndrome: diagnosis and management (Q90618941) ‎ (← links)
• Preparation of chitosan nanoparticle containing recombinant StxB antigen of EHEC and evaluation its immunogenicity in BALB/c mice (Q92376460) ‎ (← links)